Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
17.27B
Market cap17.27B
Price-Earnings ratio
17.88
Price-Earnings ratio17.88
Dividend yield
Dividend yield
Average volume
432.26K
Average volume432.26K
High today
$268.98
High today$268.98
Low today
$247.25
Low today$247.25
Open price
$247.65
Open price$247.65
Volume
969.49K
Volume969.49K
52 Week high
$282.15
52 Week high$282.15
52 Week low
$186.05
52 Week low$186.05

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $263.04, giving the company a market capitalization of 17.27B. It carries a P/E multiple of 17.88.

On 2026-08-31, Ascendis Pharma A/S(ASND) stock moved within a range of $247.25 to $268.98. With shares now at $263.04, the stock is trading +6.4% above its intraday low and -2.2% below the session's peak.

Trading volume for Ascendis Pharma A/S(ASND) stock has reached 969.49K, versus its average volume of 432.26K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

ASND News

TipRanks 5h
Ascendis Pharma Strikes Global Settlement and Licensing Deal With BioMarin Over YUVIWEL

Ascendis Pharma ( (ASND) ) has shared an announcement. On August 31, 2026, Ascendis Pharma announced a binding term sheet for a global settlement and license a...

Investing.com 12h
Jefferies lowers Ascendis Pharma stock price target on settlement - Investing.com

...

Jefferies lowers Ascendis Pharma stock price target on settlement - Investing.com
TipRanks 12h
Ascendis Pharma rises 8.0%

Ascendis Pharma (ASND) is up 8.0%, or $19.81 to $267.72. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

TipRanks 16h
Ascendis Pharma: ITC Risk Seen as Manageable, YUVIWEL Traction Supports Unchanged $345 Price Target and Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Ascendis Pharma today and set a price target of $345.00. Mitchell Kapoor has given his Buy ra...

TipRanks 17h
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

BioMarin (BMRN) announced that it has entered into binding terms with Ascendis Pharma (ASND), resolving the patent and ancillary disputes pending globally, incl...

Simply Wall St 4d
Ascendis Pharma Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug

Ascendis Pharma (NasdaqGS:ASND) presents Week 104 pivotal data on TransCon CNP (navepegritide) in achondroplasia at ISDS 2026, highlighting durable clinical out...

Ascendis Pharma Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.